|

Irinotecan Hydrochloride Clinical Trials

7 actively recruiting trials across 5 locations

Also known as: CPT 11, CPT-11, CPT11, Campto, Camptosar, Camptothecin 11, Camptothecin-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E

Gilbert, Arizona2 trials

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Banner MD Anderson Cancer Center

Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Banner MD Anderson Cancer Center

Phase 3

Other1 trial

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
Phase 3

Anchorage, Alaska1 trial

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Anchorage Associates in Radiation Medicine

Phase 2

Chicago, Illinois1 trial

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

University of Chicago Comprehensive Cancer Center

Phase 4

Bethesda, Maryland1 trial

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

National Institutes of Health Clinical Center

Phase 1

Chapel Hill, North Carolina1 trial

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.